Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Short Interest Down 28.5% in March

Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) saw a large decrease in short interest in March. As of March 31st, there was short interest totalling 3,730,000 shares, a decrease of 28.5% from the March 15th total of 5,220,000 shares. Based on an average daily volume of 448,900 shares, the days-to-cover ratio is currently 8.3 days. Approximately 7.2% of the shares of the stock are sold short.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in FULC. Mackenzie Financial Corp increased its position in Fulcrum Therapeutics by 412.5% in the 4th quarter. Mackenzie Financial Corp now owns 118,025 shares of the company's stock valued at $555,000 after acquiring an additional 94,997 shares during the period. Woodline Partners LP increased its holdings in Fulcrum Therapeutics by 110.3% in the fourth quarter. Woodline Partners LP now owns 1,410,520 shares of the company's stock valued at $6,629,000 after purchasing an additional 739,713 shares during the period. Suvretta Capital Management LLC raised its position in Fulcrum Therapeutics by 182.3% during the 4th quarter. Suvretta Capital Management LLC now owns 3,338,466 shares of the company's stock worth $15,691,000 after purchasing an additional 2,155,675 shares during the last quarter. Shay Capital LLC lifted its holdings in Fulcrum Therapeutics by 4.2% during the 4th quarter. Shay Capital LLC now owns 301,464 shares of the company's stock worth $1,417,000 after buying an additional 12,227 shares during the period. Finally, Millennium Management LLC grew its position in shares of Fulcrum Therapeutics by 224.0% in the 4th quarter. Millennium Management LLC now owns 76,123 shares of the company's stock valued at $358,000 after buying an additional 52,628 shares during the last quarter. Institutional investors own 89.83% of the company's stock.

Fulcrum Therapeutics Price Performance

NASDAQ:FULC traded down $0.07 during trading hours on Wednesday, hitting $3.58. The company's stock had a trading volume of 529,997 shares, compared to its average volume of 939,552. The company has a market capitalization of $193.24 million, a P/E ratio of -11.55 and a beta of 2.13. Fulcrum Therapeutics has a twelve month low of $2.32 and a twelve month high of $10.13. The stock has a fifty day simple moving average of $3.15 and a 200-day simple moving average of $3.61.

Fulcrum Therapeutics (NASDAQ:FULC - Get Free Report) last issued its quarterly earnings data on Tuesday, February 25th. The company reported ($0.31) earnings per share for the quarter, missing analysts' consensus estimates of ($0.28) by ($0.03). On average, equities analysts predict that Fulcrum Therapeutics will post -0.16 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a "neutral" rating and issued a $4.00 price target on shares of Fulcrum Therapeutics in a research note on Wednesday, February 26th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and two have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Hold" and a consensus target price of $8.63.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.